Compare MLGO & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLGO | MNOV |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 69.4M |
| IPO Year | 2020 | 2004 |
| Metric | MLGO | MNOV |
|---|---|---|
| Price | $4.61 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 156.2K | 33.9K |
| Earning Date | 04-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,132,230.00 | $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | $0.91 | ★ N/A |
| Revenue Growth | 6.21 | ★ 194.15 |
| 52 Week Low | $0.50 | $1.17 |
| 52 Week High | $21.18 | $1.96 |
| Indicator | MLGO | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 53.10 |
| Support Level | $4.45 | $1.31 |
| Resistance Level | $5.61 | $1.47 |
| Average True Range (ATR) | 0.50 | 0.05 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 11.41 | 86.67 |
MicroAlgo Inc is engaged in the development and application of bespoke central processing algorithms and provides solutions by integrating these algorithms with software or hardware, or both, to streamline digital services. Its services include algorithm optimization, accelerating computing power without hardware upgrades, lightweight data processing, and data intelligence services. Its technology and solutions are mainly in internet multimedia video advertising, where it provides advertising distribution solutions, software services, comprehensive solutions for enterprise customers, and intelligent chips solutions. It derives revenue from central processing algorithm services for internet advertisement and intelligent chips and services, with maximum revenue generated from Mainland PRC.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.